Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F10%3A8173" target="_blank" >RIV/00216208:11110/10:8173 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/10:8173 RIV/61989592:15110/10:33116054
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study
Original language description
Intranasal Sumatritan new two-way delivery system applied at a dose of 20 mg and 10 mg (vs. placebo) was used in 117 patients to treat migraine. Was found to improve the effectiveness of Sumatriptan 20mg (57%) and 10mg (54%) after 120 minutes compared with placebo. Side effects in relation to treatment were rare, most "metallic taste" (13/10%).
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2010
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cephalalgia
ISSN
0333-1024
e-ISSN
—
Volume of the periodical
30
Issue of the periodical within the volume
8
Country of publishing house
NO - NORWAY
Number of pages
10
Pages from-to
—
UT code for WoS article
000285054200007
EID of the result in the Scopus database
—